The Royal Liverpool and **NHS** Broadgreen University Hospitals NHS Trust



Genotypic Tropism Testing Utilisation in a UK Centre

D.C. Friday¹, L. Goodwin¹, N. H. M. Fadzillah¹, A. Chawla¹, A.M Geretti²,

¹Royal Liverpool and Broadgreen University Teaching Hospital; ²Institute of Infection & Global Health, University of Liverpool

Background

- Maraviroc (MVC) is approved in Europe for ART-experienced adults with CCR5-tropic (R5) HIV-1. BHIVA recommends its use in switch therapy (e.g. for toxicity) or after virological failure¹.
- Genotypic Tropism Testing (GTT) is recommended prior to starting MVC, based upon either plasma HIV-1 RNA or cellular HIV-1 DNA in patients with plasma HIV-1 RNA <500-1000 copies/ml.

Aim:

To review GTT use and associated MVC initiation, audit adherence to BHIVA guidelines and determine outcomes of MVC-containing ART.





Figure 3: Background Regimens used with MVC

Methods:

GTT results from Mar 2010 to Nov 2012 were identified from laboratory records and matched to clinical data. The Genotypic Susceptibility Score (GSS) of the background regimen was calculated from the Stanford HIV Resistance Database Algorithm according to 3 merged categories: susceptible/potential low-level resistance=1; low-level/intermediate resistance=0.5; high-level resistance=0.

Results

GTT results: Of 177 tests performed, 91 (51%) were from plasma HIV-1 1 RNA and 86 (49%) from cellular HIV-1 DNA. Overall, 78% plasma samples and 56% cellular samples showed R5 virus (Fig 1).



- **MVC use:** 17/119 (14.5%) patients with R5 virus started MVC. Reported reasons for MVC use are shown in Fig 2.
- At the start of MVC, patients showed median nadir CD4 count 42 cells/mm³ (range 6-309), 3 (range 0-12) previous ART regimens, 4 years (range 0-16) of previous ART, median current CD4 count 313 cells/mm³ (range 40-754) and median plasma HIV-1 RNA load (VL)


Outcomes:

After median 6 months (range 3-9), median VL decline was -1.7 log_{10} copies/ml (range 1.7- 4.2) and median CD4 count increase was 120 cells/mm³ (40-200); 12/17 (70.5%) patients had a VL <50 copies/ml. Laboratory toxicities comprised 2/17 (12%) patients experiencing mild thrombocytopaenia (100; normal range 150-400) and anaemia (9-11; normal range 13-16.8) (Table 1).

Pt.	BR	GSS BR regimen	VL at baseline	Length of follow-up	VL at end of follow-up
1	DRV/r RAL	3	<50 copies	3 months	<50 copies
2	DRV/r RAL	3	Log ₁₀ 2.6	8 months	Log ₁₀ 3.3
3	DRV/r RAL	3	Log ₁₀ 4.3	6 months	Log ₁₀ 1.5
4	DRV/r RAL TDF	3	Log ₁₀ 3.4	9 months	Log ₁₀ 3.0
5	RAL ETR	2	Log ₁₀ 2.2	6 months	Log ₁₀ 2.1
6	RAL ETR	2	<50 copies	6 months	<50 copies
7	RAL ETR ATZ/r	3	Log ₁₀ 3.3	6 months	<50 copies
8	RAL ATZ/r	3	<50 copies	3 months	<50 copies
9	DRV/r TDF	3	<50 copies	3 months	<50 copies
10	DRV/r TDF	2	Log ₁₀ 5.1	3 months	Log ₁₀ 4.2
11	DRV/r AZT	3	<50 copies	3 months	< 50 copies
12	DRV/r AZT/3TC	2	Log ₁₀ 4.8	9 months	<50 copies
13	RAL ABC TDF	3	<50 copies	3 months	<50 copies
14	RAL ABC/3TC	3	Log ₁₀ 4.0	6 months	<50 copies
15	3TC EFV	2	<50 copies	3 months	<50 copies

2.0 log₁₀ copies/ml (range <1.7-5.1). The median GSS of the background regimen was 3 (range 2-3). The drugs started with MVC are shown in Fig 3.

Figure 2: Reasons for starting MVC



Viraemia

Toxicity Switch

Intensification for poor CD4 count
Co-morbidites

Drug-drug interaction

16TDF FTC2Log103.76 months<50 copies</th>173TC NVP2<50 copies</td>3 months<50 copies</td>

Conclusion:

While MVC use was in accordance with BHIVA guidelines, GTT was overutilised in ART-naïve patients and only a small proportion of R5 results was followed by MVC initiation. Among patients who started MVC virological responses were overall good and no significant emerging toxicity was observed. Efforts are required to improve cost-effective utilisation of GTT in routine practice.

Detter Together